BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 27624329)

  • 1. Haplotype analyses of the c.1027C>T and c.2167_2168delAT recurrent truncating mutations in the breast cancer-predisposing gene PALB2.
    Catucci I; Casadei S; Ding YC; Volorio S; Ficarazzi F; Falanga A; Marchetti M; Tondini C; Franchi M; Adamson A; Mandell J; Walsh T; Olopade OI; Manoukian S; Radice P; Ricker C; Weitzel J; King MC; Peterlongo P; Neuhausen SL
    Breast Cancer Res Treat; 2016 Nov; 160(1):121-129. PubMed ID: 27624329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
    Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
    J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population.
    Pertesi M; Konstantopoulou I; Yannoukakos D
    Clin Genet; 2011 Oct; 80(4):375-82. PubMed ID: 20840220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
    Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
    Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotype analysis suggest common founders in carriers of the recurrent BRCA2 mutation, 3398delAAAAG, in French Canadian hereditary breast and/ovarian cancer families.
    Oros KK; Leblanc G; Arcand SL; Shen Z; Perret C; Mes-Masson AM; Foulkes WD; Ghadirian P; Provencher D; Tonin PN
    BMC Med Genet; 2006 Mar; 7():23. PubMed ID: 16539696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PALB2 sequencing in Italian familial breast cancer cases reveals a high-risk mutation recurrent in the province of Bergamo.
    Catucci I; Peterlongo P; Ciceri S; Colombo M; Pasquini G; Barile M; Bonanni B; Verderio P; Pizzamiglio S; Foglia C; Falanga A; Marchetti M; Galastri L; Bianchi T; Corna C; Ravagnani F; Bernard L; Fortuzzi S; Sardella D; Scuvera G; Peissel B; Manoukian S; Tondini C; Radice P
    Genet Med; 2014 Sep; 16(9):688-94. PubMed ID: 24556926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of PALB2 in a cohort of Italian breast cancer patients: identification of a novel PALB2 truncating mutation.
    Vietri MT; Caliendo G; Schiano C; Casamassimi A; Molinari AM; Napoli C; Cioffi M
    Fam Cancer; 2015 Sep; 14(3):341-8. PubMed ID: 25666743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A PALB2 germline mutation associated with hereditary breast cancer in Italy.
    Papi L; Putignano AL; Congregati C; Piaceri I; Zanna I; Sera F; Morrone D; Genuardi M; Palli D
    Fam Cancer; 2010 Jun; 9(2):181-5. PubMed ID: 19763884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of the PALB2 c.2323C>T [p.Q775X] founder mutation in well-defined breast and/or ovarian cancer families and unselected ovarian cancer cases of French Canadian descent.
    Tischkowitz M; Sabbaghian N; Hamel N; Pouchet C; Foulkes WD; Mes-Masson AM; Provencher DM; Tonin PN
    BMC Med Genet; 2013 Jan; 14():5. PubMed ID: 23302520
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel truncating PALB2 mutation and analysis of its contribution to early-onset breast cancer in French-Canadian women.
    Foulkes WD; Ghadirian P; Akbari MR; Hamel N; Giroux S; Sabbaghian N; Darnel A; Royer R; Poll A; Fafard E; Robidoux A; Martin G; Bismar TA; Tischkowitz M; Rousseau F; Narod SA
    Breast Cancer Res; 2007; 9(6):R83. PubMed ID: 18053174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and molecular characteristics of PALB2-associated cancers in Russian patients.
    Preobrazhenskaya EV; Shleykina AU; Gorustovich OA; Martianov AS; Bizin IV; Anisimova EI; Sokolova TN; Chuinyshena SA; Kuligina ES; Togo AV; Belyaev AM; Ivantsov AO; Sokolenko AP; Imyanitov EN
    Int J Cancer; 2021 Jan; 148(1):203-210. PubMed ID: 32997802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterozygous PALB2 c.1592delT mutation channels DNA double-strand break repair into error-prone pathways in breast cancer patients.
    Obermeier K; Sachsenweger J; Friedl TW; Pospiech H; Winqvist R; Wiesmüller L
    Oncogene; 2016 Jul; 35(29):3796-806. PubMed ID: 26640152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted massively parallel sequencing characterises the mutation spectrum of PALB2 in breast and ovarian cancer cases from Poland and Ukraine.
    Myszka A; Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Kitsera N; Siekierzynska A; Southey MC
    Fam Cancer; 2018 Jul; 17(3):345-349. PubMed ID: 29052111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
    García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
    Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high frequency of PALB2 mutations in Jamaican patients with breast cancer.
    Lerner-Ellis J; Donenberg T; Ahmed H; George S; Wharfe G; Chin S; Lowe D; Royer R; Zhang S; Narod S; Hurley J; Akbari MR
    Breast Cancer Res Treat; 2017 Apr; 162(3):591-596. PubMed ID: 28194609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [PALB2, a major susceptibility gene for breast cancer].
    Piffer A; Luporsi E; Mathelin C
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):701-705. PubMed ID: 30243941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tracking of the origin of recurrent mutations of the BRCA1 and BRCA2 genes in the North-East of Italy and improved mutation analysis strategy.
    Cini G; Mezzavilla M; Della Puppa L; Cupelli E; Fornasin A; D'Elia AV; Dolcetti R; Damante G; Bertok S; Miolo G; Maestro R; de Paoli P; Amoroso A; Viel A
    BMC Med Genet; 2016 Feb; 17():11. PubMed ID: 26852130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
    Tuazon AMA; Lott P; Bohórquez M; Benavides J; Ramirez C; Criollo A; Estrada-Florez A; Mateus G; Velez A; Carmona J; Olaya J; Garcia E; Polanco-Echeverry G; Stultz J; Alvarez C; Tapia T; Ashton-Prolla P; ; Vega A; Lazaro C; Tornero E; Martinez-Bouzas C; Infante M; De La Hoya M; Diez O; Browning BL; ; Rannala B; Teixeira MR; Carvallo P; Echeverry M; Carvajal-Carmona LG
    Breast Cancer Res; 2020 Oct; 22(1):108. PubMed ID: 33087180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic epidemiology of Paget's disease of bone in italy: sequestosome1/p62 gene mutational test and haplotype analysis at 5q35 in a large representative series of sporadic and familial Italian cases of Paget's disease of bone.
    Falchetti A; Di Stefano M; Marini F; Ortolani S; Ulivieri MF; Bergui S; Masi L; Cepollaro C; Benucci M; Di Munno O; Rossini M; Adami S; Del Puente A; Isaia G; Torricelli F; Brandi ML;
    Calcif Tissue Int; 2009 Jan; 84(1):20-37. PubMed ID: 19067022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.